Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avonex dose-titration versus full-dose initiation in relapsing-remitting multiple sclerosis
ACTRN12607000184471Phase 4Not yet recruiting
- Sponsor
- Biogen
- Start
- May 2007
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of interferon beta-1a in multiple sclerosis (MS) (2 arms), sponsored by Biogen. Primary endpoint: Average severity of episodes of flu-like symptoms during the 4-week titration phase. Planned start May 2007; status: not yet recruiting.
02
Drugs
interferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on ACTRN12607000184471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000184471.